MRSN RSI Chart
Last 7 days
-11.1%
Last 30 days
18.2%
Last 90 days
93.1%
Trailing 12 Months
8.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 32.3M | 38.7M | 40.8M | 36.9M |
2022 | 11.1M | 16.3M | 21.4M | 26.6M |
2021 | 0 | 0 | 0 | 6.0M |
2020 | 0 | 28.4M | 14.6M | 828.0K |
2019 | 48.6M | 44.6M | 43.3M | 42.1M |
2018 | 16.3M | 16.8M | 12.7M | 10.6M |
2017 | 25.8M | 23.3M | 26.3M | 17.5M |
2016 | 14.1M | 17.8M | 21.5M | 25.2M |
2015 | 0 | 0 | 0 | 10.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 16, 2024 | lowinger timothy b | sold | -28,208 | 2.71 | -10,409 | svp, chief sci.&tech. officer |
Jan 16, 2024 | misra tushar | sold | -9,097 | 2.71 | -3,357 | svp, chief manuf. officer |
Jan 16, 2024 | deschuytner brian | sold | -25,276 | 2.71 | -9,327 | svp, coo & cfo |
Jan 16, 2024 | bala mohan | sold | -9,298 | 2.71 | -3,431 | svp, chief development officer |
Jan 16, 2024 | mandelia ashish | sold | -13,617 | 2.71 | -5,025 | vp, chief accounting officer |
Jan 16, 2024 | protopapas anna | sold | -79,671 | 2.71 | -29,399 | - |
Jan 16, 2024 | carvajal alejandra | sold | -11,872 | 2.71 | -4,381 | svp, chief legal officer |
Jan 15, 2024 | protopapas anna | acquired | - | - | 38,958 | - |
Jan 15, 2024 | lowinger timothy b | acquired | - | - | 15,208 | svp, chief sci.&tech. officer |
Jan 15, 2024 | mandelia ashish | acquired | - | - | 5,352 | vp, chief accounting officer |
Which funds bought or sold MRSN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 464 | 464 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.83 | 6,614,830 | 14,471,200 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | reduced | -13.62 | 247,365 | 675,422 | -% |
Mar 01, 2024 | READYSTATE ASSET MANAGEMENT LP | new | - | 684,488 | 684,488 | 0.02% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | added | 4.93 | 61,151 | 127,851 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -28,000 | - | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | sold off | -100 | -129,000 | - | -% |
Feb 16, 2024 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | new | - | 36,656 | 36,656 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -13.94 | 63,000 | 174,000 | -% |
Feb 15, 2024 | Farther Finance Advisors, LLC | new | - | 2.00 | 2.00 | -% |
Unveiling Mersana Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Mersana Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 40.7B | 6.8B | -8.64 | 5.95 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.8B | 1.8B | -42.76 | 10.3 | ||||
BMRN | 16.5B | 2.4B | 98.3 | 6.81 | ||||
INCY | 12.8B | 3.7B | 21.4 | 3.46 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.41 | 17.87 | ||||
BBIO | 5.4B | - | -8.32 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.8 | 13.97 | ||||
ARWR | 3.5B | 240.7M | -11.94 | 14.72 | ||||
ACAD | 3.0B | 726.4M | -49.71 | 4.19 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.31 | 4.72 | ||||
NVAX | 669.0M | 983.7M | -1.23 | 0.68 | ||||
CRBP | 411.7M | 881.7K | -9.23 | 466.16 | ||||
INO | 324.4M | 4.9M | -2.4 | 66.66 | ||||
IBIO | 14.1M | 2.1M | -0.52 | 2.14 |
Mersana Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Revenue | 39.0% | 10,701 | 7,698 | 10,654 | 7,802 | 14,688 | 5,573 | 4,284 | 2,036 | 1,024 | 11.00 | 21.00 | 32.00 | 42.00 | 844 | 202 | 41,035 | 1,189 | 2,151 | 4,191 | 3,064 | 3,261 |
Operating Expenses | -37.8% | 32,128 | 51,639 | 67,155 | 65,603 | 60,514 | 65,212 | 56,034 | 48,588 | 48,042 | 28,772 | 22,427 | 20,584 | 16,642 | 18,137 | 17,958 | 19,586 | 23,968 | 19,560 | 16,894 | 15,827 | - |
S&GA Expenses | -21.4% | 10,134 | 12,894 | 18,187 | 18,328 | 14,805 | 14,573 | 14,803 | 12,782 | 10,674 | 5,914 | 5,881 | 5,171 | 4,212 | 4,436 | 4,192 | 4,443 | 4,152 | 4,380 | 4,231 | 3,571 | - |
R&D Expenses | -29.6% | 21,495 | 30,531 | 48,968 | 47,275 | 45,709 | 50,639 | 41,231 | 35,806 | 37,368 | 22,858 | 16,546 | 15,413 | 12,430 | 13,701 | 13,766 | 15,143 | 19,816 | 15,180 | 12,663 | 12,256 | - |
Interest Expenses | 3.0% | 1,048 | 1,017 | 1,025 | 983 | 964 | 880 | 760 | 724 | 981 | 92.00 | 92.00 | 87.00 | 87.00 | 107 | 40.00 | - | - | - | - | - | - |
Net Income | 53.1% | -19,557 | -41,656 | -54,307 | -56,163 | -44,918 | -59,811 | -52,219 | -47,258 | -48,983 | -28,844 | -22,489 | -19,786 | -16,246 | -16,792 | -17,071 | 21,901 | -22,431 | -17,069 | -12,354 | -12,403 | - |
Net Income Margin | 3.4% | -4.66* | -4.82* | -5.56* | -6.59* | -7.68* | -251.54* | -234.22* | -220.56* | -205.39* | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 30.5% | -32,348 | -46,553 | -62,233 | -29,916 | -52,014 | 54,171 | -45,433 | -8,284 | -42,555 | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -14.0% | 226 | 263 | 311 | 296 | 334 | 315 | 252 | 258 | 206 | 218 | 254 | 248 | 273 | 290 | 311 | 96.00 | 108 | 122 | 139 | 149 | 79.00 |
Current Assets | -14.3% | 214 | 250 | 297 | 282 | 319 | 300 | 237 | 241 | 189 | 199 | 233 | 232 | 259 | 275 | 295 | 80.00 | 101 | 115 | 132 | 141 | 74.00 |
Cash Equivalents | -6.3% | 175 | 186 | 129 | 123 | 129 | 184 | 135 | 230 | 178 | 192 | 227 | 228 | 255 | 271 | 288 | 60.00 | 63.00 | 58.00 | 116 | 137 | 60.00 |
Net PPE | - | - | - | - | - | 4.00 | - | - | - | 2.00 | - | - | - | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 |
Liabilities | -10.2% | 189 | 211 | 221 | 232 | 242 | 225 | 118 | 118 | 84.00 | 62.00 | 58.00 | 50.00 | 45.00 | 37.00 | 37.00 | 33.00 | 29.00 | 29.00 | 31.00 | 25.00 | 70.00 |
Current Liabilities | -6.3% | 64.00 | 68.00 | 75.00 | 83.00 | 92.00 | 89.00 | 71.00 | 56.00 | 48.00 | 44.00 | 40.00 | 35.00 | 30.00 | 21.00 | 22.00 | 17.00 | 24.00 | 22.00 | 24.00 | 23.00 | 69.00 |
Short Term Borrowings | - | 2.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt | -8.0% | 23.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 3.00 | 4.00 | 4.00 | 5.00 | 5.00 | - | - |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | 0.00 | - | - | - | 2.00 | 1.00 | 1.00 | 0.00 | - | - | - |
LT Debt, Non Current | - | 23.00 | - | - | - | 25.00 | - | - | - | 25.00 | - | - | - | 5.00 | 5.00 | 3.00 | 4.00 | 4.00 | 5.00 | 5.00 | - | - |
Shareholder's Equity | -29.3% | 37.00 | 52.00 | 90.00 | 64.00 | 92.00 | 90.00 | 134 | 141 | 122 | 156 | 196 | 198 | 228 | 253 | 274 | 63.00 | 78.00 | 93.00 | 109 | 124 | 9.00 |
Retained Earnings | -2.4% | -826 | -806 | -765 | -710 | -654 | -609 | -549 | -497 | -450 | -401 | -356 | -315 | -280 | -251 | -229 | -209 | -192 | -176 | -159 | -142 | -164 |
Additional Paid-In Capital | 0.5% | 863 | 859 | 855 | 775 | 747 | 700 | 684 | 638 | 572 | 557 | 552 | 513 | 508 | 505 | 503 | 272 | 271 | 269 | 268 | 266 | 173 |
Shares Outstanding | 0.1% | 121 | 121 | 120 | 109 | 105 | 98.00 | 88.00 | 80.00 | 71.00 | 70.00 | 69.00 | 69.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 364 | - | - | - | 403 | - | - | - | 800 | - | - | - | 1,148 | - | - | - | 164 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 30.6% | -31,962 | -46,081 | -61,834 | -29,005 | -51,229 | 54,597 | -44,776 | -7,955 | -42,400 | -36,098 | -34,468 | -27,022 | -17,319 | -20,196 | -15,935 | -21,246 | -12,576 | -16,284 | -14,197 | -24,687 | -15,904 |
Share Based Compensation | 2.1% | 4,085 | 4,001 | 6,643 | 6,407 | 5,314 | 5,375 | 5,348 | 5,485 | 4,860 | 4,928 | 4,582 | 4,039 | 1,989 | 1,918 | 1,656 | 1,609 | 1,262 | 1,285 | 1,161 | 1,164 | 1,128 |
Cashflow From Investing | -80.6% | 20,148 | 103,778 | -5,439 | 1,396 | -45,426 | -16,491 | -90,470 | -329 | -155 | -46.00 | -333 | -114 | -188 | 2,805 | 14,975 | 19,435 | 16,500 | -41,768 | -12,153 | 10,128 | 13,723 |
Cashflow From Financing | 163.0% | 92.00 | -146 | 73,180 | 21,549 | 41,458 | 10,638 | 40,527 | 60,394 | 28,795 | 463 | 33,916 | 472 | 1,665 | -49.00 | 228,886 | -90.00 | 231 | -8.00 | 5,277 | 92,204 | 211 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Collaboration revenue | $ 36,855 | $ 26,581 | $ 43 |
Operating expenses: | |||
Research and development | 148,269 | 173,385 | 132,013 |
General and administrative | 59,543 | 56,963 | 36,888 |
Restructuring expenses | 8,713 | 0 | 0 |
Total operating expenses | 216,525 | 230,348 | 168,901 |
Other income (expense): | |||
Interest income | 12,073 | 2,883 | 65 |
Interest expense | (4,073) | (3,328) | (1,267) |
Total other income (expense), net | 8,000 | (445) | (1,202) |
Net loss | (171,670) | (204,212) | (170,060) |
Other comprehensive loss: | |||
Unrealized gain (loss) on marketable securities | 163 | (152) | 0 |
Comprehensive loss | (171,507) | (204,364) | (170,060) |
Net loss attributable to common stockholders - basic | (171,670) | (204,212) | (170,060) |
Net loss attributable to common stockholders - diluted | $ (171,670) | $ (204,212) | $ (170,060) |
Net loss per share attributable to common stockholders — basic (in dollars per share) | $ (1.48) | $ (2.18) | $ (2.41) |
Net loss per share attributable to common stockholders — diluted (in dollars per share) | $ (1.48) | $ (2.18) | $ (2.41) |
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares) | 116,112,891 | 93,654,243 | 70,580,949 |
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares) | 116,112,891 | 93,654,243 | 70,580,949 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 174,561 | $ 128,885 |
Short-term marketable securities | 34,523 | 151,827 |
Accounts receivable | 0 | 30,000 |
Prepaid expenses and other current assets | 4,973 | 8,507 |
Total current assets | 214,057 | 319,219 |
Property and equipment, net | 3,831 | 3,985 |
Operating lease right-of-use assets | 7,694 | 10,475 |
Other assets, noncurrent | 478 | 661 |
Total assets | 226,060 | 334,340 |
Current liabilities: | ||
Accounts payable | 7,319 | 13,951 |
Accrued expenses | 21,898 | 43,184 |
Deferred revenue | 28,147 | 30,610 |
Operating lease liabilities | 3,252 | 2,798 |
Short-term debt | 2,083 | 0 |
Other current liabilities | 938 | 990 |
Total current liabilities | 63,637 | 91,533 |
Operating lease liabilities, noncurrent | 5,149 | 8,575 |
Long-term debt, net | 23,148 | 24,929 |
Deferred revenue, noncurrent | 97,167 | 117,043 |
Other liabilities, noncurrent | 55 | 203 |
Total liabilities | 189,156 | 242,283 |
Commitments (Note 15) | ||
Stockholders' equity | ||
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 0 | 0 |
Common stock, $0.0001 par value; 350,000,000 shares authorized; 120,711,745 and 105,144,864 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 12 | 11 |
Additional paid-in capital | 863,242 | 746,889 |
Accumulated other comprehensive income (loss) | 11 | (152) |
Accumulated deficit | (826,361) | (654,691) |
Total stockholders’ equity | 36,904 | 92,057 |
Total liabilities and stockholders’ equity | $ 226,060 | $ 334,340 |
Common stock, shares authorized (in shares) | 350,000,000 | 350,000,000 |